XML 32 R30.htm IDEA: XBRL DOCUMENT

Concentration of credit risk (Tables)

9 Months Ended

Sep. 30, 2019

Concentration of credit risk

Schedule of concentration of credit risk related to collaborative partners

In December 2009, we entered into a license, development and commercialization agreement with Lilly. In November 2009, we entered into a collaboration and license agreement with Novartis. In December 2018, we entered into a research collaboration and licensing agreement with Innovent Biologics, Inc. (“Innovent”). In July 2019, we entered into a collaboration and license agreement with Zai Lab (Shanghai) Co., Ltd., a subsidiary of Zai Lab Limited (collectively, “Zai Lab”). The concentration of credit risk related to our collaborative partners is as follows:


		Percentage of Total					Percentage of Total
		Milestone and Contract Revenues for the					Milestone and Contract Revenues for the
		Three Months Ended					Nine Months Ended
		September 30,					September 30,
		2019		2018			2019		2018
Collaboration Partner A		—	%	—	%		—	%	—	%
Collaboration Partner B		—	%	100	%		—	%	100	%
Collaboration Partner C		—	%	—	%		77	%	—	%
Collaboration Partner D		100	%	—	%		23	%	—	%

Schedule of concentration of credit risk related to specialty pharmacy customers

In November 2011, we began commercialization and distribution of JAKAFI to a number of customers. Our product revenues are concentrated in a number of these customers. The concentration of credit risk related to our JAKAFI product revenues is as follows:


		Percentage of Total Net					Percentage of Total Net
		Product Revenues for the					Product Revenues for the
		Three Months Ended					Nine Months Ended
		September 30,					September 30,
		2019		2018			2019		2018
Customer A		20	%	19	%		19	%	20	%
Customer B		14	%	12	%		14	%	13	%
Customer C		16	%	16	%		16	%	15	%
Customer D		11	%	12	%		12	%	11	%